Yesintek, formerly known as Bmab 1200, is a human interleukin-12 and -23 antagonist. The FDA has approved Yesintek (Ustekinumab-kfce), a biosimilar to Stelara (Ustekinumab), for the treatment of ...

YESINKTEK is the sixth ustekinumab biosimilar approved by the FDA, behind Amgen’s WEZLANA (ustekinumab-auub), approved in Oct. 2023; Alvotech’s SELARSDI (ustekinumab-aekn), approved in April 2024; ...

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...

Planegg-Martinsried, Germany / Amman, Jodan – Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into a licensing and supply agreement for the ...

The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with ...

After filing a new drug submission for its ustekinumab biosimilar PYZCHIVA (Janssen’s STELARA), Samsung commenced the ...

Results of a Phase III study conducted by an international team of researchers reveal that mirikizumab is more effective and ...

A key provision of the Inflation Reduction Act (IRA) of 2022 directed Medicare to negotiate the prices of certain top-selling ...

Mean duration of Crohn's disease was 7.4 years. Nearly half (48.5%) had previous biologic therapy failure, 45.7% had previous ...

Germany’s Formycon has entered into a licensing and supply agreement with MS Pharma for the commercialization of FYB202, ...

The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases.

The US Food and Drug Administration (FDA) has approved ustekinumab -kfce (Yesintek) as a biosimilar to ustekinumab (Stelara) for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, ...